AB Science publishes the good news of clinical phase III of oligotic drugs

Source: Sina medicine 2017-05-22 amyotrophic lateral sclerosis (ALS), also known as progressive frostbite, is a very rare neurodegenerative disease There has been a lack of effective drug therapy for this disease for many years In recent years, researchers have been working to add new therapeutic options to this disease field Recently, AB science, a French pharmaceutical company, released favorable data of phase III clinical study of its drug masitinib treatment (ALS) When masitinib was combined with Rilutek, Sanofi's only approved ALS drug on the market, the progress of patients' disease was about 27% slower than that of Rilutek alone, according to the data In addition to the patient's remission in the 48 week follow-up period after treatment, the drug can also prolong the progression free survival period of patients This result is also consistent with previous masitinib research data The company is currently planning to submit its application for conditional approval to the EU EMA However, the announcement of this good news did not arouse a warm response from investors Just a day ago, the EU's medical administration rejected another application for the drug to treat the rare disease, still systemic mastocytosis In fact, the process of AB science's development of masitinib can be described as a series of setbacks EU regulators have previously vetoed the drug's application to market for the treatment of pancreatic cancer and gastrointestinal stromal tumors In addition, masitinib has previously been used to treat animals with mast cell tumors AB science firmly believes that it can be applied to some indications of human beings, but the results of recent efforts show little effect In addition to continuing to work in the area of ALS, AB Science said it would ask EU managers to re-examine the application of masitinib for the treatment of static systemic mastocytosis In recent years, the society has paid more attention to ALS patients Thanks to some policy support from the pharmaceutical management department, many ALS drug research and development have been on the fast track Recently, FDA approved the launch of radicava developed by Mitsubishi Tanabe pharma The drug is expected to go on sale in August this year In addition, considering the extreme lack of drug therapy for ALS, FDA also considers further reducing the data threshold of such therapy to change the current situation Masitinib is an oral tyrosine kinase inhibitor targeting at csf1r The researchers believe the drug protects neurons from neurodegenerative processes triggered by small, dysfunctional glial cells and reduces inflammation in the patient's focal area At present, AB science company is still carrying out further research on the indications of masitinib in the treatment of Alzheimer's disease, multiple sclerosis, asthma, rheumatoid arthritis and a variety of tumors.